


Viral Hepatitis – A Global Pandemic



Viral HBV and HCV are the main causes of liver cancer, but up to **90%** of people are unaware they have the condition⁴

Hepatitis means **inflammation of the liver**, and it is often caused by a virus: **VIRAL HEPATITIS**

There are 5 types of hepatitis:


- A (HAV)
- B (HBV)
- C (HCV)
- D (HDV)
- E (HEV)

All of these viruses cause short term infection or acute infection. However HBV, HCV and HDV can cause long-term infection, called **chronic hepatitis**, which can lead to life-threatening complications such as **cirrhosis** (liver scarring), **liver failure**, and **liver cancer**¹

Hepatitis is often asymptomatic, but if symptoms do occur, they can include:^{2,3}



Global burden



Impact of the disease


60-70% of patients with HCV will develop chronic infection⁷



5-20% of patients with HCV develop liver cirrhosis;² of which 7% will develop hepatocellular carcinoma (HCC)⁸




20-30% of patients with HBV develop liver cirrhosis, and 25% of people will develop HCC⁸



Chronic HCV is the leading cause of liver transplantations⁹




There is currently no vaccine for HCV⁴, but the vaccine for HBV is effective in 95% of cases³



HCV is one of the most common viral liver diseases;² it has six identified genotypes and more than 50 subtypes^{9,10}

Transmission

Viral hepatitis is spread through blood-to-blood contact¹¹, but HBV can also be spread through the exchange of bodily fluids¹



of the world's 16 million people who inject drugs have HCV⁹

HBV and HCV risk factors include:⁹

- Haemodialysis
- Body piercings and tattoos
- Sharing razors or toothbrushes
- Children born to infected mothers
- Sexual contact with an infected person



Treatment

HCV

Dual therapy

Pegylated interferon-alfa and ribavirin cure rates:^{12,13,14}

- **40-50%** of genotype 1
- Over **90%** of genotype 2
- Over **65%** of genotype 3
- Up to **70%** of genotype 4

Triple therapy

Protease inhibitors in combination with pegylated interferon and ribavirin⁹

- Cures up to **80%** of cases of treatment naive genotype 1 chronic HCV patients⁹



HBV

Not everyone with HBV needs treatment, however for those with chronic HBV, interferons and antiviral agents are available³

Liver Cancer Awareness Month is an annual international health campaign organised by liver cancer charities, patient groups and other related organisations every October. It is intended to increase awareness of the diseases contributing to liver cancer, the relevant preventative interventions and to raise funds for further research into its cause, prevention, diagnosis, treatment and cure

References

1. World Hepatitis Alliance. About Viral Hepatitis. Available at: <http://www.worldhepatitisalliance.org/en/about-viral-hepatitis.html> [Last accessed August 2013].
2. World Health Organization. Media Centre: Hepatitis C. July 2013. Available at: <http://www.who.int/mediacentre/factsheets/fs164/en/> [Last accessed August 2013].
3. World Health Organization. Media Centre: Hepatitis B. July 2013. Available at: <http://www.who.int/mediacentre/factsheets/fs204/en/> [Last accessed August 2013].
4. ELPA. Liver Cancer Prevention: Getting viral hepatitis under control. European Week Against Cancer 2013. 29 May 2013. Available at http://www.easl.eu/assets/application/files/785d69feecfb1ba_file.pdf. [Last accessed August 2013].
5. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012; 380: 2095-128.
6. CDC. Hepatitis B. Available at: <http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview>. [Last accessed September 2013].
7. Economist Intelligence Unit. The Silent Pandemic: Tackling Hepatitis C with Policy Innovation. January 2013
8. Blachier M, Leleu H, Peck-Radosavljevic M. The Burden of liver disease in Europe: A review of available epidemiological data. *European Association for the Study of the Liver* 2013.
9. Lang K, Weiner DB. Immunotherapy for HCV infection: next steps. *Expert Review of Vaccines* 2008;7(7): 915-923.
10. Simmonds P. Reconstructing the origins of human hepatitis viruses. *Philosophical Transactions of the Royal Society B: Biological Sciences* 2001;Jul 29;356(1411):1013-26.
11. Esteban JI, Saulede S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. *Journal of Hepatology* 2008;48:148-162.
12. McHutchison J, EJ Lawitz, ML Shiffman et al. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. *New England Journal of Medicine* 2009;361:580-93.
13. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. *New England Journal of Medicine* 2009;360:1839-50.
14. HepMag - Your Guide to Hepatitis. Hepatitis C: The Basics. Available at: http://www.hepmag.com/articles/2512_18756.shtml [Last accessed September 2013].

For more information: Please consult your doctor who can advise you on viral hepatitis management and available treatment options

